Min Dong
department
Medical Oncology
Introduction

Min Dong, MD,PhD

?

Title

Associate chief physician of Medical Oncology

?Master’s supervisor


Research Interests

Basic and clinical research of breast cancer

Basic and clinical research of hepatocellular carcinoma

Basic and clinical research of gastric carcinoma

Palliative therapy of advanced cancer

?

Education and Experience

Training

·Internal medicine department of the third affiliated hospital of Sun Yat-Sen University (Sep 1999-Jun 2002)

Residencies

·Hematology department of the third affiliated hospital of Sun Yat-Sen University (Jul 2002-Dec 2004)

Attending Physician

·Hematology department of the third affiliated hospital of Sun Yat-Sen University (Jan 2005-Jun 2005)

·Medical Oncology department of the third affiliated hospital of Sun Yat-Sen University (Jul 2005-Dec 2012)

Associate Chief Physician

·Medical Oncology department of the third affiliated hospital of Sun Yat-Sen University (Jan 2013 up to now)

?

Honors and Awards

Medical Science & Technology Research Foundation of Guangdong Province, 2009

Science & Technology Foundation of Guangdong Province, 2011

The National Natural Science Foundation of China, 2016

?

Publications

1. Dong M, Wang HY, Zhao XX, Chen JN, Zhang YW, Huang Y, Xue L, Li HG, Du H, Wu XY, Shao CK. Expression and prognostic roles of PIK3CA, JAK2, PD-L1 and PD-L2 in EBV-associated gastric carcinoma. Hum Pathol. 2016; 53: 25-34.

2. Dong M, Fan XJ, Chen ZH, Wang TT, Li X, Chen J, Lin Q, Wen JY, Ma XK, Wei L, Ruan DY, Lin ZX, Liu Q, Wu XY, Wan XB. Aberrant expression of enhancer of zeste homologue 2, correlated with HIF-1α, refines relapse risk and predicts poor outcome for breast cancer. Oncol Rep. 2014; 32(3):

1101-7.

3. Li X, Zhong X, Chen ZH, Xing YF, Wu DH, Chen J, Ma XK, Lin Q, Wen JY, Wei L, Wang TT, Ruan DY, Lin ZX, Wu XY, Dong M. Hepatitis B virus DNA negativity acts as a favorable prognostic factor in hepatocellular carcinoma patients. Asian Pac J Cancer Prev. 2014; 15(22): 9635-41.

4. Dong M, Wan XB, Yuan ZY, Wei L, Fan XJ, Wang TT, Lv YC, Li X, Chen ZH, Chen J, Lin Q, Wen JY, Ma XK, Liu Q, Wu XY. Low expression of Beclin 1 and elevated expression of HIF-1α refine distant metastasis risk and predict poor prognosis of ER-positive, HER2-negative breast cancer. Med Oncol, 2013; 30(1): 355-364.

5. Zhang XF, Dong M, Pan YH, Chen JN, Huang XQ, Jin Y, Shao CK. Expression pattern of cancer-associated fibroblast and its clinical relevance in intrahepatic cholangiocarcinoma. Hum Pathol, 2017; 65:92-100.

6. Li X, Dong M, Lin Q, Chen ZH, Ma XK, Xing YF, Wan XB, Wen JY, Wei L, Chen J, Wu XY. Comparison of current staging systems for advanced hepatocellular carcinoma not amendable to locoregional therapy as inclusion criteria for clinical trials. Asia Pac J Clin Oncol, 2013; 9(1):86-92.

7. Zhang Y, Chen JN, Dong M, Zhang ZG, Zhang YW, Wu JY, Du H, Li HG, Huang Y, Shao CK. Clinical Significance of Spasmolytic Polypeptide-expressing Metaplasia and Intestinal Metaplasia in EBV-associated and EBV-negative Gastric Cancer. Hum Pathol. 2017; 63:128-138.

8. Wan XB, Wei L, Li H, Dong M, Lin Q, Ma XK, Huang PY, Wen JY, Li X, Chen J, Ruan DY, Lin ZX, Chen ZH, Liu Q, Wu XY, Hong MH. High pretreatment serum lactate dehydrogenase level correlates with disease relapse and predicts an inferior outcome in locally advanced nasopharyngeal carcinoma. Eur J Cancer. 2013; 49(10):2356-2364.

9. Wu XY, Chen J, Cao QH, Dong M, Lin Q, Fan XJ, Xia Q, Chen ZH, Liu Q, Wan XB. Beclin 1 activation enhances chemosensitivity and predicts a favorable outcome for primary duodenal adenocarcinoma. Tumour Biol. 2013; 34(2):713-722.

10. Li X, Lin Q, Dong M, Wen JY, Wei L, Ma XK, Chen ZH, Wu XY. Prognostic analysis of acute exacerbations of hepatitis-B after chemotherapy in combination with rituximab in 19 patients with lymphoma. Leuk Lymphoma, 2010; 51(9): 1678-1685.


Contact

Department of Medical Oncology, the Third Affiliated Hospital, Sun Yat-sen University

600 Tianhe Rd, Guangzhou

Phone: +86-20-85252161

E-mail: dongmin@mail.sysu.edu.cn